Amicus Therapeutics (FOLD) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

FOLD Amicus Therapeutics

Watchlist

11.505
-0.075-0.65%

Trading Oct 31 14:12 ET

3.41BMarket Cap-29500P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
GlobeNewswireOct 28 07:00 ET
TD Cowen Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20
Moomoo NewsOct 23 07:31 ET · Ratings
Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates?
Zacks Oct 18 11:30 ET
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
Zacks Oct 18 11:00 ET
Teva Settles Patent Litigation With Amicus
Seeking AlphaOct 18 10:18 ET
How Much Upside Is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44%
Zacks Oct 18 09:05 ET

Comments

Meltyy

May 16 01:29

🔔 Perceptive Advisors Q1 ‘24* Holdings Released... 🐳

» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
...

Moomoo AI

Feb 7 06:42

Despite Amicus Therapeutics' recent share price uptick and steady revenue growth, the market's high expectations are reflected in the share price fall over the past three years. The company's 3.2% total shareholder return over the last twelve months falls short of the market return.

Strong Week for Amicus Therapeutics (NASDAQ:FOLD) Shareholders Doesn't Alleviate Pain of Three-year Loss

Moomoo AI

Jan 3 05:28

Investors might overlook Amicus Therapeutics' below industry-level growth forecast, risking future disappointment if the P/S ratio falls in line with the growth outlook. Moderate P/S ratio poses a risk as weaker revenue outlook might lead to share price drop.